HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase III HARMONi-GI1 trial (AK112-309). The study evaluated first-in-class ivonescimab plus...
Hence then, the article about positive overall survival results from the phase iii harmoni gi1 trial of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in first line biliary tract cancer presented at the esmo 2026 presidential symposium was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium )
Also on site :
- Elvis Presley Estate Sues AI Company for Training Use of 274 ‘Iconic’ Songs Without Permission
- 1989 Classic Cover, Hailed as One of Dolly Parton’s ‘Best Songs of All Time,’ Gets New Life by Reba McEntire
- Christopher Abbott Gushes Over Welcoming First Child with Partner Aubrey Plaza: ‘It’s Like the Best Movie Ever’